The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2022-09-09
DOI
10.1016/j.annonc.2022.09.150
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements.
- (2022) Lipika Goyal et al. JOURNAL OF CLINICAL ONCOLOGY
- Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial
- (2022) Vivek Subbiah et al. NATURE MEDICINE
- Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma
- (2021) Thomas Boerner et al. HEPATOLOGY
- A comprehensive characterization of the cell-free transcriptome reveals tissue- and subtype-specific biomarkers for cancer detection
- (2021) Matthew H. Larson et al. Nature Communications
- FGFR2 Extracellular Domain In-Frame Deletions are Therapeutically Targetable Genomic Alterations that Function as Oncogenic Drivers in Cholangiocarcinoma
- (2021) James M. Cleary et al. Cancer Discovery
- Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study
- (2021) Milind Javle et al. LANCET ONCOLOGY
- Cell-free DNA captures tumor heterogeneity and driver alterations in rapid autopsies with pre-treated metastatic cancer
- (2021) Bernard Pereira et al. Nature Communications
- Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF/FGFR aberrations: a phase I dose-expansion study
- (2021) Funda Meric-Bernstam et al. Cancer Discovery
- Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation
- (2021) Andrew X. Zhu et al. JAMA Oncology
- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma
- (2020) Melanie A. Krook et al. MOLECULAR CANCER THERAPEUTICS
- Identification of FGFR2/3 fusions from clinical cfDNA NGS using a de novo fusion caller.
- (2020) Arielle Yablonovitch et al. JOURNAL OF CLINICAL ONCOLOGY
- Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
- (2020) Ghassan K Abou-Alfa et al. LANCET ONCOLOGY
- Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
- (2020) Ghassan K Abou-Alfa et al. LANCET ONCOLOGY
- Cholangiocarcinoma 2020: the next horizon in mechanisms and management
- (2020) Jesus M. Banales et al. Nature Reviews Gastroenterology & Hepatology
- Futibatinib is a novel irreversible FGFR 1-4 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors
- (2020) Hiroshi Sootome et al. CANCER RESEARCH
- Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
- (2020) Aurélien Marabelle et al. LANCET ONCOLOGY
- Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial
- (2020) Vivek Subbiah et al. LANCET ONCOLOGY
- Molecular and clinicopathological characteristics of ROS1 ‐rearranged non‐small cell lung cancers identified by next generation sequencing
- (2020) Meiying Cui et al. Molecular Oncology
- Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies
- (2020) Yoshiaki Nakamura et al. NATURE MEDICINE
- Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib
- (2020) Ian M. Silverman et al. Cancer Discovery
- Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference
- (2020) Kendal Jensen et al. JAMA Oncology
- TAS-120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure
- (2019) Maria Kalyukina et al. ChemMedChem
- Association of JAK2-V617F Mutations Detected by Solid Tumor Sequencing With Coexistent Myeloproliferative Neoplasms
- (2019) Gregory Riedlinger et al. JAMA Oncology
- Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid
- (2019) Alexandra M. Miller et al. NATURE
- Molecular Analysis of Plasma From Patients With ROS1-Positive NSCLC
- (2019) Ibiayi Dagogo-Jack et al. Journal of Thoracic Oncology
- Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma
- (2019) Paola Bertuccio et al. JOURNAL OF HEPATOLOGY
- TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma
- (2019) Lipika Goyal et al. Cancer Discovery
- Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors
- (2019) Shuyan Dai et al. Cells
- Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
- (2019) Alessandro Leonetti et al. BRITISH JOURNAL OF CANCER
- Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma
- (2019) Steven B. Maron et al. CLINICAL CANCER RESEARCH
- Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients with ALK+ lung cancer
- (2019) Leora Horn et al. Journal of Thoracic Oncology
- Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164
- (2019) Dung T. Le et al. JOURNAL OF CLINICAL ONCOLOGY
- Genotyping of circulating tumor DNA in cholangiocarcinoma reveals diagnostic and prognostic information
- (2019) T. J. Ettrich et al. Scientific Reports
- Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer
- (2019) Seyed Pairawan et al. CLINICAL CANCER RESEARCH
- Comprehensive molecular profiling of intra- and extrahepatic cholangiocarcinomas: potential targets for intervention
- (2018) Maeve A Lowery et al. CLINICAL CANCER RESEARCH
- The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients
- (2018) Oliver A. Zill et al. CLINICAL CANCER RESEARCH
- Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies
- (2018) Justin I. Odegaard et al. CLINICAL CANCER RESEARCH
- Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
- (2018) Milind Javle et al. JOURNAL OF CLINICAL ONCOLOGY
- Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma
- (2018) Liang-Qing Dong et al. JOURNAL OF HEPATOLOGY
- Characteristics and Outcome of ROS1 -Positive Non–Small Cell Lung Cancer Patients in Routine Clinical Practice
- (2018) Sehhoon Park et al. Journal of Thoracic Oncology
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid Tumors
- (2018) Ryan N. Ptashkin et al. JAMA Oncology
- Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer
- (2018) Jingying Nong et al. Nature Communications
- Regional differences in gallbladder cancer pathogenesis: Insights from a multi-institutional comparison of tumor mutations
- (2018) Raja R. Narayan et al. CANCER
- COSMIC: the Catalogue Of Somatic Mutations In Cancer
- (2018) John G Tate et al. NUCLEIC ACIDS RESEARCH
- Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK )- rearranged non-small cell lung cancer
- (2017) Ka-Won Noh et al. JOURNAL OF PATHOLOGY
- IDH2 Mutation in a Patient with Metastatic Colon Cancer
- (2017) Bing M. Zhang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overall Survival and Clinical Characteristics of BRCA‐Associated Cholangiocarcinoma: A Multicenter Retrospective Study
- (2017) Talia Golan et al. ONCOLOGIST
- Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors
- (2017) Viktor A. Adalsteinsson et al. Nature Communications
- BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers
- (2017) Kara N. Maxwell et al. Nature Communications
- Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
- (2017) Alexander Drilon et al. Cancer Discovery
- New Horizons for Precision Medicine in Biliary Tract Cancers
- (2017) Juan W. Valle et al. Cancer Discovery
- Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma
- (2017) Apinya Jusakul et al. Cancer Discovery
- Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer
- (2017) John H. Strickler et al. Cancer Discovery
- AACR Project GENIE: Powering Precision Medicine through an International Consortium
- (2017) Cancer Discovery
- Intratumoral heterogeneity of intrahepatic cholangiocarcinoma
- (2017) Dirk Walter et al. Oncotarget
- Biliary cancer: Utility of next-generation sequencing for clinical management
- (2016) Milind Javle et al. CANCER
- Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise
- (2016) Supriya K. Saha et al. ONCOLOGIST
- Polyclonal SecondaryFGFR2Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma
- (2016) Lipika Goyal et al. Cancer Discovery
- Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma
- (2014) Rondell P. Graham et al. HUMAN PATHOLOGY
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
- (2014) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
- (2014) Siddhartha Jaiswal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape of intrahepatic cholangiocarcinoma
- (2014) Shanshan Zou et al. Nature Communications
- Contribution of p53 to Metastasis
- (2014) E. Powell et al. Cancer Discovery
- Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma
- (2013) Yasuhito Arai et al. HEPATOLOGY
- Exome sequencing identifies distinct mutational patterns in liver fluke–related and non-infection-related bile duct cancers
- (2013) Waraporn Chan-on et al. NATURE GENETICS
- Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas
- (2013) Yuchen Jiao et al. NATURE GENETICS
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
- (2012) Sandra Misale et al. NATURE
- Exome sequencing of liver fluke–associated cholangiocarcinoma
- (2012) Choon Kiat Ong et al. NATURE GENETICS
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan
- (2010) T Okusaka et al. BRITISH JOURNAL OF CANCER
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
- (2010) Juan Valle et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation